In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...
Moderna integrates extensive research and development with both in-house and partner manufacturing to rapidly develop and ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Telemark Asset Management, LLC established a new position in Moderna ( MRNA +6.66%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has ...
Researchers showed that an mRNA influenza vaccine delivered with their new lipid nanoparticle could generate the same immune ...
Morgan Stanley lowered the firm’s price target on Moderna (MRNA) to $30 from $32 and keeps an Equal Weight rating on the shares. Published first ...
Moderna Inc became the second U.S company to release data from a large study of its experimental vaccine, saying it was 94.5% effective against COVID-19.
A stunning new study offers early evidence that COVID-19 vaccines might have a secret superpower: A precisely timed mRNA shot could help many cancer patients live longer.
Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, overshadowed quarterly sales and profit above market expectations as premium ...
Research reveals mRNA COVID-19 vaccines may enhance cancer immunotherapy effectiveness, extending survival for lung and skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback